SinoMab BioScience's (HKG:3681) phase 1B China clinical trial of its SM17 drug for moderate-to-severe atopic dermatitis reached its primary endpoints, according to a Monday filing with the Hong Kong bourse.
The drug was well-tolerated during the 16-week trial and follow-up period and showed no serious adverse events, the filing said.
SM17 also showed skin healing effects, while lower doses of the drug showed relief from pruritus or itching compared with those treated with a placebo, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.